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httpIn vivo assessment of endothelial function in human
lower extremity arteries
Vikram S. Kashyap, MD,a Ryan O. Lakin, MD,a Lindsay E. Feiten, BS,b Paul D. Bishop, MSEE,b and
Timur P. Sarac, MD,c Cleveland, Ohio
Objective: Endothelial function has been measured in preclinical studies in human brachial and coronary arteries but not in
lower extremity arteries affected by atherosclerosis. We describe a novel, ﬁrst-in-man evaluation of endothelial function of
the superﬁcial femoral arteries (SFAs) in patients with peripheral arterial disease (PAD).
Methods: Enrolled were 25 patients with PAD requiring lower extremity angiography. Endothelial-dependent relaxation
was measured using intravascular ultrasound (IVUS) imaging and a Doppler ﬂow wire after the infusion of acetylcholine
(Ach). IVUS-derived virtual histology of the same vessel was calculated. Endothelial-independent relaxation was
measured with an infusion of nitroglycerin (200 mg). Levels of nitric oxide and serum nitric oxide metabolites were
determined by laboratory analysis.
Results: Patients (48% male; mean age, 62 years) had a history of hypertension (80%), coronary disease (36%), and diabetes
(40%). The mean SFA diameter was 5.2 6 1 mm (range, 3.2-6.9 mm). Patients tolerated Ach infusion with no adverse
events. Endothelial-dependent relaxation increased over baseline for all patients with Ach infusion of 10L6 to 10L4. At
Ach 10L4, diameter (0.5%) and area (1.8%) changes in the diseased SFAs were modest and insigniﬁcant; however, average
peak velocity of blood ﬂow signiﬁcantly increased 26%, 46%, and 63% with an Ach 10L6 to 10L4 infusion. Calculations of
limb volumetric ﬂow (68% at Ach 10L4) were signiﬁcantly increased after Ach infusion. Lower extremity nitric oxide
levels were slightly lower than systemic venous levels (P [ .04). Nitroglycerin infusion indicated normal smooth muscle
responsiveness (3% diameter, 9% area, and 116% velocity change over baseline). IVUS-virtual histology plaque stratiﬁ-
cation indicated predominantly ﬁbrous morphology (46%; necrotic core, 29%; calcium, 18%). Atheroma burden was
14.9 6 5.5 mm3/cm and did not correlate with endothelial responsiveness.
Conclusions: Endothelial function can be measured directly in human lower extremity arteries at the sites of vascular
disease. Despite extensive atherosclerosis, endothelial function is still intact. These data support the application of
regional endothelial-speciﬁc biologic therapies in patients with PAD. (J Vasc Surg 2013;58:1259-66.)The importance of the vascular endothelium and its
interaction with nitric oxide (NO) has led researchers to
focus on analyzing function in both normal and disease
states.1-3 The healthy vascular endothelium acts as a para-
crine, endocrine, and autocrine organ regulating multiple
important homeostatic functions.4 Vasorelaxation can occur
through endothelial-dependent vasorelaxation (EDR) or
endothelial-independent vasorelaxation (EIR). Through
interaction with endothelial cell-surface receptors, media-
tors of EDR (acetylcholine [Ach], bradykinin, etc) signal
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mediated vasorelaxation. Endothelial dysfunction is also
believed to herald abnormality in the development of
atherosclerosis.5
Early clinical studies of human endothelial function
involved local infusion of Ach with measurement of the
change in coronary vessel diameter by quantitative angiog-
raphy.6-9 Noninvasive methods were developed thereafter
incorporating ultrasound (US) imaging of NO-mediated
brachial artery reactive hyperemia.10 Recently, reactive
hyperemia-peripheral arterial tonometry has emerged as
a reliable noninvasive technique to assess peripheral micro-
vascular endothelial function.11-14
Despite these techniques and promising advances, the
data outcomes primarily focus on epicardial vessel correla-
tion and cardiovascular risk assessment.15-19 Furthermore,
little information is obtained about the atherosclerotic pla-
que involved in the disease process. Endothelial function
measured in normal, nonatherosclerotic brachial vessels
may be of little relevance to the remnant endothelial func-
tion in a severely diseased lower extremity artery. There
remains a technical gap in the ability to directly assess endo-
thelial function in human lower extremity arteries.
Intravascular US (IVUS) imaging is a new technology
that permits tomographic visualization of a cross-section
through the vessel wall. Its development has provided
a powerful new method to assess plaque morphology
in vivo. Recent clinical studies have documented its1259
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ingly used to assist in selecting and evaluating therapeutic
intervention.20-22 Current IVUS catheters, which are as
small as 0.9 mm in diameter, permit the interrogation of
most areas of the human arterial vasculature. In addition,
spatial resolution is of the order of 80 to 100 mm radially
and 150 to 200 mm circumferentially.
In addition to plaque composition, gated IVUS
imaging can allow sensitive measurement of luminal diam-
eter and arterial area. In combination with infusion of vaso-
active agonists, endothelial function can be determined
directly. The simultaneous measurement of arterial blood
ﬂow velocity using a Doppler guidewire represents a
complimentary technique for sensitive determination of
endothelial function in vivo.
We hypothesized that we could evaluate endothelial
function directly in the blood vessels affected by atheroscle-
rosis. In this project, we describe a novel assay using
a combination of angiography, IVUS, a ﬂow wire, and
infusion of endothelial agonists. This approach directly
allows quantiﬁcation of endothelial function and assess-
ment of atherosclerosis in the same area. We believe this
ﬁrst-in-man approach will allow further understanding of
endothelial dysfunction in patients with peripheral arterial
disease (PAD) by correlating endothelial function in vivo
to the morphology of arterial plaque and systemic risk
factors.
METHODS
The protocol for this study was approved by the In-
vestigational Review Board (ClinicalTrials.gov identiﬁer:
NCT00848302).
Patients. Study participants were recruited from the
Departments of Vascular Surgery and Cardiology and
comprised 25 patients with chronic lower extremity
occlusive disease who required lower extremity diagnostic
angiography, most in preparation for a percutaneous inter-
vention or surgical revascularization. All participants
provided written informed consent for the study, including
performance of IVUS concurrent with angiography and
infusion of arterial agonists.
The inclusion criteria were (1) age $18 years; (2)
symptoms of intermittent claudication, rest pain, or minor
tissue loss (Rutherford category I-V)23; (3) noninvasive
vascular laboratory evidence of PAD, including depressed
ankle-brachial indices or pulse volume recording, or arterial
duplex US conﬁrming occlusive disease; and (4) angio-
graphic demonstration of a patent segment of superﬁcial
femoral artery (SFA) allowing IVUS catheter introduction.
Exclusion criteria included (1) acute limb ischemia,
deﬁned by a signiﬁcant worsening of symptoms in the prior
2 weeks; (2) contraindication to angiography (creatinine
>2.5 mg/dL); and (3) concurrent oral anticoagulant
therapy that could not be safely withheld. Antiplatelet
therapy was not stopped for the procedures.
Clinical data were entered in a Web-based (intranet)
case report form and abstracted electronically into a dedi-
cated Health Insurance Portability and AccountabilityAct-compliant Oracle database during a single ofﬁce visit.
Demographic variables were recorded, including baseline
medical comorbidities, including hypertension, diabetes
(type 1 or 2), coronary artery disease, chronic renal insufﬁ-
ciency, chronic obstructive lung disease, and obesity. A
history of smoking, ethanol, and family history of coronary
or peripheral vascular disease was elicited. Preprocedural
laboratory studies performed for this study included fasting
blood glucose, hemoglobin A1c (in diabetic participants),
cholesterol proﬁle, homocysteine, and high-sensitive
C-reactive protein.
Angiography, EDR, EIR. Participants underwent
diagnostic angiography through a contralateral femoral
artery approach. An appropriate sized sheath (eg, 6F Raabe
sheath; Cook Medical Inc, Bloomington, Ind) was placed
up and over the aortic bifurcation and into the target
artery near the area to be evaluated for endothelial func-
tion. A heparin bolus (3000-5000 U) was given at the time
of long sheath placement. Standard diagnostic arterio-
graphic images were obtained.
Next, wire exchange to a 0.014-inch DopplerFlow wire
(Volcano Corp, Rancho Cordova, Calif) was performed.
This guidewire was used to place an Eagle Eye IVUS cath-
eter (20-MHz probes; Volcano Corp) to obtain US data
from the SFA or very proximal popliteal artery (Fig 1). In
some patients, atherosclerotic occlusive disease prevented
passage of the IVUS catheter into the vascular segment
distal to the stenotic disease, and data acquisition termi-
nated at the most distal extent of patent vessel. Calciﬁca-
tion of the vessel did not preclude precise diameter, area,
or ﬂow measurements.
In most patients, a percutaneous intervention was per-
formed at the same sitting after the investigational studies.
Thus, IVUS interrogation, EDR, and EIR were performed
before any intervention. EDR and EIR determination were
performed at the same sites of IVUS morphologic data
acquisition. In addition to IVUS, the DopplerFlow wire
was used for volumetric ﬂow and velocity estimation.
For endothelial function studies, EDR and EIR were
measured. EDR was measured by assessing the percentage
change in axial diameter over baseline values after infusion
of Ach through the sheath side arm. The incremental doses
of molar concentrations of 106, 105, and 104 were
mixed by the main hospital pharmacy into 1-mL aliquots
before the procedure and delivered fresh to the operating
room. Ach was infused with stepwise increasing doses of
106, 105, and 104 for 1 minute at each concentration.
Ach infusion was performed under a U.S. Food and Drug
Administration Investigational New Drug (Application
105,683, June 5, 2009) protocol. Electrocardiogram-
gated systolic IVUS axial diameter measurements were
made 30 seconds after each infusion dose for EDR. Simul-
taneous determination of the average peak velocity (APV)
by the DopplerFlow wire was recorded. Heparinized saline
(20 mL) was used to wash out the Ach before nitroglycerin
(NTG) infusion.
EIR to conﬁrm smooth muscle function in the media
was done with a single dose of NTG (200 mg) with
Fig 1. In this lower extremity angiogram performed with an
intravascular ultrasound (IVUS) catheter and a 0.014-inch
Doppler ﬂow wire, the IVUS probe is approximately at marker
200 (arrow) and the wire sensor is beyond marker 240.
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sion. Quantitation of diameter changes included baseline
diameter, absolute change in vessel diameter, and
percentage change in diameter.
All procedures were performed in an endovascular
operating room with cardiopulmonary monitoring and
conscious sedation using midazolam and fentanyl. No
adverse events related to the study procedure occurred in
these 25 patients.
IVUS and virtual histology. IVUS data were
acquired during 10-cm pullbacks. IVUS images were
collected to Super-VHS and these data were transferred to
the hard drive of a personal computer for processing, as
described previously.24,25 Brieﬂy, quantitative IVUS char-
acterization of plaque composition was performed with
radiofrequency analysis of the unprocessed US signal.
Frequency analyses of the backscattered signal were per-
formed using Volcano Image Analysis Software 3.0.
The luminal and medial-adventitial borders were then
detected using a deformable model algorithm. Any re-
quired user correction of the borders was performed with
custom-designed border-editing tools. After segmentation,luminal and medial-adventitial cross-sectional area, maxi-
mum and minimum diameter, and eccentricity index
were determined. The difference between the medial-
adventitial border (demarcating the boundary of the
plaque-media complex with the surrounding adventitia)
and the luminal border (demarcating the area of free
lumen) deﬁned the plaque area. IVUS measurements
were performed in accordance with the standards of the
American College of Cardiology and the European Society
of Cardiology.26 Our methods were similar to those used in
A Study to Evaluate the Effect of Rosuvastatin on Intravas-
cular Ultrasound-Derived Coronary Atheroma Burden
(ASTEROID)27 and Reversal of Atherosclerosis with
Aggressive Lipid Lowering (REVERSAL)28 trials, and
previous reports have established the accuracy and repro-
ducibility of these methods.29
Areas comprising calcium, collagen ﬁbers, and necrotic
core were identiﬁed on the corresponding IVUS image
using a modiﬁed virtual histology algorithm. Fig 2, A is
a B-mode IVUS image from a lower extremity artery.
Fig 2, B is the border analysis documenting luminal and
medial-adventitial borders. Virtual histology is performed
using a modiﬁed coronary artery algorithm classiﬁed by
color indicating calcium (white), necrosis (red), and ﬁbrous
(green) plaque components (Fig 2, C).
Chemiluminescence. Levels of NO were determined
using a Sievers 280i NO detector (GE Analytical Instru-
ments, Boulder, Colo) that is sensitive to the picomole
level for liquid samples. Blood samples were drawn from
an antecubital vein and at the level of IVUS interrogation
by using a guiding catheter or sheath sideport. This
allowed comparison of systemic vs local NO levels. The
plasma components of these samples were separated and
evaluated by the chemiluminescent assay for nitrate/nitrite
metabolites of NO (NOx) using the manufacturer’s
instructions for the detector. All samples were run in
duplicate.
Statistical analysis. Diameter change (mm), area
change (mm2), and APV change (mm/s) were calculated
with the equation (Postinfusion valuebaseline value)/
baseline value).
Limb volumetric ﬂow (Q) was calculated using the
following equation based on previous work by Newby
and Fox30 and others31,32: Q ¼ area (mm2)  APV
(mm/s) ¼ mm3/s or mL/s.
All data reported are means 6 standard error of the
mean. Statistical signiﬁcance was set at P < .05. Dose-
response curves for hemodynamics and blood ﬂow were
analyzed by one-way analysis of variance. Single compari-
sons were made with a two-tailed Student paired and
unpaired t-test. Statistical analysis was performed with
GraphPad Prism 6.0 software (GraphPad Software, La
Jolla, Calif).
RESULTS
Demographic and clinical factors are reported in
Table I. The 25 patients (48% male) were a mean age of
62 6 16 years. Most patients had risk factors for
Table I. Demographic and clinical factors of the 25
study patients
Patient variables No. (%) or mean 6 SD
Age, years 62 6 16
Male sex 12 (48)
Coronary artery disease 9 (36)
Hypertension 20 (80)
Diabetesa 10 (40)
Tobacco use 21 (84)
Aspirin or other antiplatelet use 19 (76)
Total cholesterol, mg/dL 176 6 46
Creatinine, mg/dL 1.4 6 1.9
Homocysteine, mmol/L 11.4 6 4.8
C-reactive protein, mg/L 17 6 28
SD, Standard deviation.
aIncludes insulin-dependent and noninsulin-dependent diabetes.
Fig 2. A, B-mode intravascular ultrasound (IVUS) image of an artery depicts the three layers of the arterial wall. B,
Border analysis documents luminal (light blue) and medial-adventitial (dark blue) borders, C, Virtual histology is
performed using a modiﬁed coronary artery algorithm classiﬁed by color, indicating calcium (white), necrosis (red), and
ﬁbrous (green) plaque components.
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diabetes (40%), and smoking (80%, current or remote
user). Evidence of coronary disease was present in nine
patients (36%).
The mean SFA diameter was 5.2 6 1 mm (range, 3.2-
6.9 mm). Patients tolerated Ach infusion with no adverseevents. EDR increased over baseline for all patients with
Ach infusion 106 to 104. Endothelial function, as
measured by diameter changes, was 1 to 3 mm, with corre-
spondingly small percentage changes (0.5% at Ach 104).
Cross-sectional area changes were also small and statisti-
cally insigniﬁcant. We observed a 1.1% increase in area at
an Ach dose of 106, 1.4% at Ach 105, and 1.8% at Ach
104. These changes in the diseased SFA were modest.
However, APV of blood ﬂow signiﬁcantly increased
26%, 46%, and 63% with Ach 106 to 104 infusion
(Fig 3) in a nearly step-wise fashion. Calculations of blood
ﬂow (diameter  APV, mm2/s) showed signiﬁcant
changes of 26%, 46%, and 67% with Ach 106 to 104.
Similarly, limb volumometric ﬂow, Q (area  APV, mL/
s), also showed signiﬁcant increases (68%) for Ach 104
(Fig 4). NTG infusion indicated normal smooth muscle
responsiveness (3% diameter, 9% area, and 116% velocity
change over baseline) in all vessels.
Lower extremity levels of NO and NOx had an absor-
bance value of 153 6 14 and were slightly lower than
systemic venous levels at 215 6 26 (P ¼ .04; Fig 5). The
areas of endothelial function assessment were also interro-
gated with a 10-cm IVUS pullback. This allowed IVUS-
virtual histology plaque stratiﬁcation using a semiautomated
Fig 3. Average peak velocity (APV) showed statistically signiﬁcant
increases of 26%, 46%, and 63% in response to incremental doses of
acetylcholine (Ach). The error bars show the standard error of the
mean. P ¼ .0012 by analysis of variance. EDR, Endothelial-
dependent vasorelaxation.
Fig 4. Percentage change in limb volumetric ﬂow showed statis-
tically signiﬁcant increases in response to incremental doses of
acetylcholine (Ach). The error bars show the standard error of the
mean. P ¼ .0014 by analysis of variance. EDR, Endothelial-
dependent vasorelaxation.
Fig 5. Lower extremity levels of nitric oxide metabolites (NOx)
were slightly lower than systemic venous levels. P ¼ .0395. The
error bars show the standard error of the mean.
JOURNAL OF VASCULAR SURGERY
Volume 58, Number 5 Kashyap et al 1263algorithm. The arteries in these patients were diseased with
atherosclerosis. The plaque morphology was 46% ﬁbrous
plaque, with necrotic core (29%) and calcium plaque
(18%) less common morphologies. Atheroma burden was
14.9 6 5.5 mm3/cm. Neither atheroma burden nor pla-
que morphology was correlated with endothelial respon-
siveness (Table II).
DISCUSSION
The results of our studies of endothelial function are
novel and compelling. We were able to use IVUS to accu-
rately assess diameter and area changes in the SFA. True
axial diameters were obtained. In addition, a ﬂow wireallowed measurement of the velocity of blood ﬂow in the
arteries examined. Taken together, changes in volumetric
blood ﬂow in the limb were obtained. These studies indi-
cate that EDR and EIR can be measured at the time of
angiography and intervention.
Our results indicate that diseased lower extremity
arteries may not dilate signiﬁcantly with NO because of
the stiffness of atherosclerotic vessels. However, infusion
of Ach led to large increases in blood ﬂow in the limb.
This raises the implication that the more distal vasculature
underwent vasodilation or that there was decreased resis-
tance in the extremity. These effects were beyond our
IVUS-mediated measurements of diameter and area. In
addition, the microcirculation may have responded to
Ach infusion.
Our preclinical studies of lower extremity endothelial
function were based on ex vivo tissue bath ring studies.33
Human anterior tibial and popliteal arteries were expedi-
tiously harvested from above-knee amputations and
assessed for endothelial function. EDR was measured as
a function of vessel relaxation in response to incremental
doses of Ach, similar to this protocol. A compelling
outcome was the ability of atherosclerotic vessels to retain
their ability to vasodilate. These ex vivo results provided
rationale for the in vivo method of assessing human lower
extremity function described in this report.
Ludmer et al6 ﬁrst described the technique of assessing
endothelial function in diseased coronary arteries using
quantitative angiography. Graded concentrations of Ach
were infused into the left anterior descending artery of
eight patients with advanced coronary stenoses. Four
patients with angiographically normal coronary arteries
and six with mild coronary atherosclerosis were used for
comparison. In the four normal coronary arteries, Ach
caused a dose-dependent dilation from the baseline. In
contrast, the diseased arteries showed dose-dependent
constriction. The authors concluded that paradoxic vaso-
constriction induced by Ach occurs in early and late stages
of coronary atherosclerosis.
Table II. Correlation of clinical variables and
endothelial-dependent relaxation assessed by using limb
volumetric ﬂowa
Variable
Correlation
coefﬁcient R
Coefﬁcient of
determination R2 P
Age, years 0.3 0.09 .18
CRP, mg/L 0.2 0.04 .44
Cholesterol, mg/dL 0.4 0.17 .06
Plaque CSA, mm2 0.003 <.001 .99
CRP, C-reactive protein; CSA, cross-sectional area.
aNone of the variables examined correlated to endothelial-dependent
relaxation curves.
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the effects of an intracoronary injection of Ach on coronary
arterial hemodynamics and diameter changes in adults
with normal/benign coronary arteriographic ﬁndings. A
signiﬁcant increase in coronary sinus blood ﬂow and a
signiﬁcant decrease in coronary vascular resistance occurred
after the intracoronary injection of Ach. In contrast, mean
diameter of the epicardial coronary artery tended to
decrease. Intracoronary injection of Ach increased coronary
blood ﬂow, suggesting vasodilation in the coronary arteri-
olar bed, while it induced vasoconstriction in most epicar-
dial coronary arteries in adult humans. These results
indicated that Ach-induced coronary vasoconstriction is
variable in the absence of severe disease and even high-
lighted varying responses to Ach along the course of the
coronary artery.
The incorporation of a Doppler velocity catheter
allowed Hodgson et al9 to determine the integrated effects
of Ach on epicardial diameter, coronary ﬂow, and vascular
resistance. Patients with nonstenotic epicardial vessels
underwent coronary angiography with simultaneous
recording of coronary ﬂow velocity using a Doppler cath-
eter. Measurements of arterial epicardial cross-sectional
area (ECA), velocity, estimated ﬂow (velocity  area),
and vascular resistance were made before and after bolus
administration of Ach and papaverine. Ach stimulus
resulted in a 19% reduction of ECA, whereas papaverine
increased ECA by 9%. Estimated ﬂow increased 69% after
Ach and 147% after papaverine. Resistance fell after both
agents (Ach, 17%; papaverine, 61%). The results
suggested that Ach has differing effects on the epi-
cardial arteries (constriction) and the smaller resistance
vessels (dilation), the net response to Ach depends on
endothelial-dependent vasodilation, and analyzing
the effects of Ach on the coronary circulation requires
determination of both ﬂow and artery diameter. This
method has been repeated in multiple series and is consid-
ered the gold standard for testing coronary endothelial
function.4,36
Celermajer et al10 introduced a novel method in 1992
to assess peripheral vascular diameter changes in response
to reactive hyperemia. Given its noninvasive nature, ﬂow-
mediated dilation (FMD) has become a widely usedtechnique to assess endothelial function. FMD uses shear
stress to induce NO release after a 5-minute occlusion of
the brachial artery. Initial results of asymptomatic men
and women with known coronary risk factors demon-
strated that reduced ﬂow-mediated dilation was indepen-
dently associated with cigarette smoking, older age, male
gender, and larger vessel size.37
Correlation of endothelial function was subsequently
reported in human coronary and brachial artery reactivity.
Anderson et al15 administered intracoronary infusions of
Ach to 50 patients, followed by endothelium-dependent
vasodilation assessment in the brachial artery in response
to reactive hyperemia. Patients with coronary artery vaso-
constriction in response to Ach had signiﬁcantly impaired
ﬂow-mediated vasodilation in the brachial artery compared
with patients with normal coronary endothelial function.
Their multivariate analysis showed the strongest predictors
of reduced FMD were baseline brachial artery diameter,
coronary endothelial dysfunction, the presence of coronary
artery disease, and cigarette smoking.
A prospective study conducted by Gokce et al38 exam-
ined the long-term predictive value of FMD for future
cardiovascular events in 199 patients undergoing elective
vascular procedures. Patients were prospectively monitored
for an average of 1.2 years after surgery. During the follow-
up period, 35 patients had a cardiovascular event, including
cardiac death, myocardial infarction, unstable angina, and
stroke; of these events, 15 occurred$30 days after surgery.
Preoperative FMD was signiﬁcantly lower in patients with
an event than in those without an event. The authors
concluded that impaired brachial artery endothelial func-
tion independently predicted short-term and long-term
cardiovascular events and that assessment of endothelial
function using the brachial artery FMD might serve as
a surrogate end point for cardiovascular risk in patients
with PAD.
Despite these successful reports of patient data, scru-
tiny of the FMD technique remains widespread, mainly
due to inadequate guidelines and operator-dependent
error.39,40 This issue is highlighted in reports by the Euro-
pean Society of Cardiology41 and the American Heart
Association/American College of Cardiology,42 which
state that FMD studies are not recommended for cardio-
vascular risk assessment and are designated as class III
recommendations. Furthermore, FMD has not been estab-
lished as a functional assessment of peripheral vascular
disease and tests an artery that is rarely affected by athero-
sclerosis. In contradistinction to FMD, where the diameter
of a normal brachial artery can increase dramatically, our
studies show that velocity of blood ﬂow increases in
response to endothelial agonists.
Our preliminary work has several limitations. Our
patient selection was limited to individuals undergoing
electively planned angiograms with atherosclerosis. Addi-
tional imaging in younger, healthier patients with normal
vessels would be illuminating. However, enrollment of
these patients with normal lower extremity vessels without
the need for lower extremity angiography would be
JOURNAL OF VASCULAR SURGERY
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during angiography.
Similar to the work by Horio et al,34,35 the velocity and
volume ﬂow changes in our study were signiﬁcantly
increased with Ach infusion, yet the diameter of the
measured vessels did not change signiﬁcantly. Studies look-
ing at the distal vasculature were not part of this protocol
but could help conﬁrm this physiologic process. Our
results, taken together with coronary data, indicate that
Ach infusion leads to downstream NO production rather
than at the sites a few centimeters distal to the infusion.
Given the small numbers in this initial trial, the conclu-
sion that endothelial function does not correlate with
degree of plaque burden or plaque morphology may be
premature. Plaque cross-sectional area was highly variable
in these 25 patients. We hypothesized that increasing
calcium or necrotic plaque burden would negatively affect
EDR, which we did not ﬁnd, presumably because of the
small numbers in this pilot study. Further studies are
currently underway to determine the effects of L-arginine
supplementation on lower extremity endothelial function.
Ideally, human clinical studies in this arena will include
chronic and acute limb ischemia conditions.
CONCLUSIONS
We describe a novel, ﬁrst-in-man approach to measure
endothelial function in lower extremity arteries in patients
with PAD. Volumetric ﬂow increases in the limb with
Ach infusion and NO are present despite extensive athero-
sclerosis. This method will allow further understanding of
endothelial dysfunction in the setting of PAD and can be
used for assessing biologic therapies targeted for PAD.
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